Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 276 to 300 of 392

Guidance and quality standards awaiting development
Title	Type
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy [TSID10764]	Technology appraisal guidance
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy [TSID10763]	Technology appraisal guidance
Rusfertide for treating polycythaemia vera in people having phlebotomy [ID6709]	Technology appraisal guidance
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]	Technology appraisal guidance
Ruxolitinib for treating moderate atopic dermatitis [ID6602]	Technology appraisal guidance
Sabizabulin for treating COVID 19 [TSID11814]	Technology appraisal guidance
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6592]	Technology appraisal guidance
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]	Technology appraisal guidance
Sacituzumab tirumotecan for treating advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma after 2 or more treatment lines [ID6723]	Technology appraisal guidance
Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal	Quality standard
Safeguarding adults in care homes	Quality standard
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]	Technology appraisal guidance
Satralizumab for treating thyroid eye disease [ID6648]	Technology appraisal guidance
Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]	Technology appraisal guidance
Secondary care management of malignant hypertension	Quality standard
Secukinumab for treating relapsed polymyalgia rheumatica [ID6599]	Technology appraisal guidance
Selinexor for maintenance treatment of p53 wild-type advanced or recurrent endometrial cancer after systemic treatment [TSID12374]	Technology appraisal guidance
Selinexor with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 to 4 treatment lines in people who have not had pomalidomide [ID6705]	Technology appraisal guidance
Selinexor with ruxolitinib for treating splenomegaly or symptoms in myelofibrosis untreated with a JAK inhibitor [ID6717]	Technology appraisal guidance
Semaglutide 7.2 mg single-dose device for managing overweight and obesity [ID6699]	Technology appraisal guidance
Semaglutide for managing overweight and obesity in children 6 to 11 years [TSID12381]	Technology appraisal guidance
Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6635]	Technology appraisal guidance
Semaglutide for treating type 2 diabetes [ID1450]	Technology appraisal guidance
Sepiapterin for treating hyperphenylalaninaemia in phenylketonuria in people of any age [ID6750]	Technology appraisal guidance
Serplulimab with chemotherapy for neoadjuvant and adjuvant treatment of untreated gastric cancer [ID6760]	Technology appraisal guidance

Results per page

10
25
50
All